Open label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder.

Open label, Multi center Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder (OAB).

Inclusion Criteria:

• Women 18 years or older, inclusive
• Diagnosis of OAB or mixed incontinence with the predominance of OAB symptoms
• Dissatisfaction with any current or previous pharmacotherapy treatment of OAB for any reason within the past 12 months
• Treatment Satisfaction VAS <50
• Ability to understand and sign ICF
• Subject agreed to attend all follow up evaluations and was willing to completely and accurately fill out voiding diaries and questionnaires, and was willing to complete required exams and tests
• Subject agreed not to participate in another research study from the time of screening until the final study visit
• Subject agreed not to use a pharmacotherapy treatment for OAB from the time of screening until the final study visit

Exclusion Criteria:

• Prior treatment with botulotoxin for OAB
• Previous pharmacotherapy for OAB if >12 months ago
• Urinary retention with post void residual > 150ml
• Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and nerves of lower limbs
• History or presence of stress incontinence, or mixed incontinence where stress incontinence was predominant

females age 18 years or older. The women had a diagnosis of OAB or mixed incontinence with the predominance of OAB symptoms. The women were dissatisfied with current or previous pharmacotherapy treatment of OAB for any reason within the past 12 months.